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Abstract
Background: Barrett's esophagus (BE) is the metaplastic replacement of squamous with columnar epithelium in the esophagus,
as a result of reflux. It is the major risk factor for the development of esophageal adenocarcinoma (EAC). Methylation of CpG
dinucleotides of normally unmethylated genes is associated with silencing of their expression, and is common in EAC. This study
was designed to determine at what stage, in the progression from BE to EAC, methylation of key genes occurs.
Results: We examined nine genes (APC, CDKN2A, ID4, MGMT, RBP1, RUNX3, SFRP1, TIMP3, and TMEFF2), frequently
methylated in multiple cancer types, in a panel of squamous (19 biopsies from patients without BE or EAC, 16 from patients
with BE, 21 from patients with EAC), BE (40 metaplastic, seven high grade dysplastic) and 37 EAC tissues. The methylation
frequency, the percentage of samples that had any extent of methylation, for each of the nine genes in the EAC (95%, 59%, 76%,
57%, 70%, 73%, 95%, 74% and 83% respectively) was significantly higher than in any of the squamous groups. The methylation
frequency for each of the nine genes in the metaplastic BE (95%, 28%, 78%, 48%, 58%, 48%, 93%, 88% and 75% respectively) was
significantly higher than in the squamous samples except for CDKN2A and RBP1. The methylation frequency did not differ
between BE and EAC samples, except for CDKN2A and RUNX3 which were significantly higher in EAC. The methylation extent
was an estimate of both the number of methylated alleles and the density of methylation on these alleles. This was significantly
greater in EAC than in metaplastic BE for all genes except APC, MGMT and TIMP3. There was no significant difference in
methylation extent for any gene between high grade dysplastic BE and EAC.
Conclusion: We found significant methylation in metaplastic BE, which for seven of the nine genes studied did not differ in
frequency from that found in EAC. This is also the first report of gene silencing by methylation of ID4 in BE or EAC. This study
suggests that metaplastic BE is a highly abnormal tissue, more similar to cancer tissue than to normal epithelium.
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The incidence of esophageal adenocarcinoma (EAC) is
increasing rapidly and patient outcomes remain poor.
Known risk factors for EAC include obesity, gastro-
esophageal reflux, and the presence of Barrett's esophagus
(BE). Repeated injury from gastro-duodenal reflux is
thought to result in the replacement of the esophageal
squamous mucosa with a metaplastic columnar lined epi-
thelium. The presence of goblet cells within columnar epi-
thelium is diagnostic for BE. Approximately 0.5 – 1% of
patients with BE will develop EAC each year and patients
with BE have a 50- to 100-fold increased risk of EAC com-
pared to the general population [1,2].
The progression from BE to EAC is generally accepted to
proceed via the histological stages of low-grade and high-
grade dysplasia. Progress along this pathway appears to
mirror the accumulation of genetic abnormalities, with a
number of reports suggesting a stepwise progression of
genetic changes. Abnormalities in CDKN2A, seen in BE
metaplastic tissue, followed by altered TP53 expression,
generally reported in dysplastic tissue, have been associ-
ated with the transition from BE to EAC [3,4]. Alterations
in the expression of many other genes have also been
described at different stages of the progression to cancer
[5,6].
Genes can be aberrantly down-regulated as a result of
genomic alterations such as mutation, deletion, or DNA
methylation. In humans, methylation of cytosines gener-
ally occurs in the context of a CpG dinucleotide. Regions
of relatively high CpG content, termed CpG islands, are
found in the promoter region of many genes. Methylation
within these regions is associated with suppression of the
expression of certain genes, for example the switching off
of key developmental genes in adult tissues. However,
aberrant methylation of normally unmethylated CpG
islands is a common cause of altered gene expression in
cancer. As esophageal biopsies are easily obtained at
endoscopy, it is possible to determine at what stage meth-
ylation occurs during the progression to cancer. In this
study we compared the methylation of nine genes, fre-
quently methylated in other cancers, between squamous,
BE and EAC tissues.
Results
Gene methylation and expression in esophageal cancer 
cell lines
Methylation and expression of the nine genes listed in
Table 1 were measured in triplicate cultures of the esopha-
geal cancer cell lines OE33 and TE7, following treatment
with either 5-aza-2'-deoxycytidine (aza-dC) or vehicle
(Figure 1). Methylation was observed in all genes in
OE33, except APC and CDKN2A, while in TE7 it was only
observed in ID4, RBP1, SFRP1, and TMEFF2. Treatment
with aza-dC reduced methylation and significantly
increased the expression of all methylated genes except
TMEFF2, which was undetected in either cell line.
CDKN2A was not detected in TE7 by methylation PCR or
quantitative real-time reverse-transcription PCR (qRT-
PCR), suggesting that the gene was deleted in this cell line.
Following treatment with aza-dC, transcript levels were
not significantly increased for any unmethylated genes,
except for APC in OE33.
Methylation in esophageal adenocarcinoma and Barrett's 
esophagus
The results in Figure 2 show the methylation frequency,
the percentage of samples that had any extent of methyla-
tion, for each of the nine genes, in squamous tissues from
either patients with no known history of BE (S), or
patients with BE (S-BE) or patients with adenocarcinoma
(S-EAC), in metaplastic Barrett's from patients with BE but
no dysplasia or adenocarcinoma (BE), in high grade dys-
plastic Barrett's from patients with adenocarcinoma (D-
EAC), and in adenocarcinoma (EAC). In squamous tis-
sues the methylation frequency for each gene did not dif-
fer significantly between S and S-BE, while in S-EAC
methylation was significantly higher for SFRP1 (com-
pared to either S or S-BE) and ID4 (compared to S) and
lower for APC (compared to S-BE). For all nine genes the
methylation frequency in BE and D-EAC was significantly
higher than each of the squamous tissues (S, S-BE and S-
EAC) with the exception of CDKN2A (no difference
Table 1: The primer sequences and annealing temperatures for methylation analysis
Gene Forward primer Reverse primer Annealing temperature (°C)
APC GAAGYGGAGAGAGAAGTAGTTG ACRAACTACACCAATACAACCACATA 55
CDKN2A TYGGYGGYGGGGAGTAGTATGGAGTTT RTTAAACAACRCCCCCRCCTCCAACAA 60
ID4 GGGGYGTAYGGTTTTATAAATATAGTTG TAATCACTCCCTTCRAAACTCCGACTAAA 55
MGMT 5G5GTTT5GGATATGTTGGGATAGTT AC5AAAC5ACCCAAACACTCACCAAA 55
RBP1 TGTGYGYGTTGGGAATTTAGTTG CRAAAAATAACTAAAACCAATTAACCACAAA 55
RUNX3 YGTYGTTTTTTGYGTTTTGAGGTT ACTTAAATCTACRAAAATACRCATAACAA 55
SFRP1 ATTTTYGGGAGTYGGGGYGTATT RACCAATAACRACCCTCRACCTA 57
TIMP3 TTTGAGGGGGYGGGTTTTAATAGTT AACRACCTCCCRACGAAAAAACAAA 55
TMEFF2 TTGTTTTTTYGTYGGGTGTTATTGTTAT AACAAACRACTTCCRAAAAACACAAA 55Page 2 of 12
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Molecular Cancer 2008, 7:75 http://www.molecular-cancer.com/content/7/1/75Methylation and expression of APC, CDKN2A, ID4, MGMT, RBP1, RUNX3, SFRP1, TIMP3 and TMEFF2 in esophageal cancer cell lines OE33 and TE7Figur  1 (see pr vious page)
Methylation and expression of APC, CDKN2A, ID4, MGMT, RBP1, RUNX3, SFRP1, TIMP3 and TMEFF2 in 
esophageal cancer cell lines OE33 and TE7. The esophageal cancer cell lines OE33 and TE7 were treated with either 1 
μmol/L aza-dC or vehicle for 72 hours. The medium was replaced with fresh medium only, and the cells incubated for a further 
24 hours before harvesting. Bisulphite modified DNA was amplified using primers and PCR conditions (Table 2) which were 
specific for bisulphite modified DNA, did not discriminate between methylated and unmethylated sequences, and did not 
amplify unmodified DNA. The PCR products were melted by increasing the temperature from 60 to 95°C, rising 0.5 or 1°C at 
each step, waiting 30 seconds on the first step then 5 seconds for each step thereafter. Data was collected and analysed using 
the Melt Curve Analysis function of the RG-3000 Application Software. The left hand column shows the melt curves for each 
of the nine genes for OE33, the central column for TE7. Each plot shows the melt curves for the unmethylated (black lines) and 
methylated (open circles) controls and the cell lines treated with vehicle (red circles) or aza-dC (green circles). The horizontal 
axis represents temperature and the vertical axis -dF/dT. CDKN2A was not amplified in TE7. Interpretation of the melt curves 
is described in the Materials and Methods. The right hand column shows the gene expression in cell lines treated with vehicle 
(red columns) or aza-dC (green columns), as determined by qRT-PCR and normalised to HMBS. Data shown are the means ± 
SD from three independent experiments. TMEFF2 expression was below detectable limits in either cell line treated with vehi-
cle or aza-dC.Page 4 of 12
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Methylation frequency and methylation extent in esophageal tissuesFigure 2
Methylation frequency and methylation extent in esophageal tissues. Methylation of each gene was measured in mul-
tiple biopsies of squamous mucosa (S, n = 19) from seven patients without BE, single biopsies of squamous mucosa (S-BE, n = 
16) and multiple biopsies of columnar mucosa (BE, n = 40) from 18 patients with BE, single biopsies of squamous mucosa (S-
EAC, n = 21), high grade dysplastic Barrett's (D-EAC, n = 7) and tumor (EAC, n = 37) from 38 patients with EAC. The methyl-
ation was graded as unmethylated (white), methylated 1 (yellow), 2 (red), or 3 (blue), as described in the Materials and Meth-
ods.
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Molecular Cancer 2008, 7:75 http://www.molecular-cancer.com/content/7/1/75between BE or D-EAC and S or S-BE), RBP1 (BE vs S-BE
and D-EAC vs S or S-BE) and SFRP1 (D-EAC vs S-EAC).
There were no differences between BE and D-EAC. The
methylation frequency for all nine genes was significantly
higher in EAC than any squamous tissue. There were no
differences between EAC and D-EAC. There were no dif-
ferences between EAC and BE, except for CDKN2A and
RUNX3, which were significantly higher in EAC than BE
(P = 0.0104 and 0.0358 respectively).
The methylation extent, which reflects the combination of
both the number of methylated alleles and the density of
methylation of those alleles, was graded on a scale of 1–3,
with 1 being low and 3 being high methylation (Figure 2).
The methylation extent in EAC was significantly greater
than in BE for all genes, except for APC, MGMT and
TIMP3. There were no significant differences in methyla-
tion extent between EAC and D-EAC.
The number of genes methylated in each specimen is
shown in Figure 3. Significantly more genes were methyl-
ated in specimens of BE, D-EAC and EAC, compared to
any of the squamous tissues (P < 0.01 for each compari-
son). There were no significant differences between any of
the squamous tissues, nor between BE, D-EAC and EAC.
Methylation and gene expression in esophageal tissues
We examined the relationship between methylation and
gene expression in tissues from patients with EAC, from
which sufficient RNA was available (Figure 4). The expres-
sion of APC, CDKN2A, MGMT, RUNX3, TIMP3 and
TMEFF2 did not differ significantly between EAC, D-EAC
and S-EAC. There was significantly less expression of ID4,
RBP1 and SFRP1 in EAC compared to S-EAC, and of ID4
and SFRP1 in EAC compared to D-EAC (Figure. 4a).
We then looked for an association between the presence
of methylation and a reduction in gene expression within
the EAC tissues. There was no significant difference in
APC, CDKN2A, ID4, RBP1, RUNX3 and TIMP3 expres-
sion levels between methylated and unmethylated
tumors. There were too few SFRP1 unmethylated tissues
for this analysis. There was significantly less expression of
MGMT in methylated tumors compared to unmethylated
tumors (Figure. 4b). Furthermore, the expression of
MGMT did not differ between unmethylated squamous
and unmethylated tumor tissues, suggesting that the
observed reduction in EAC was primarily due to methyla-
tion, not phenotypic differences.
Discussion
Methylation is an important mechanism for the silencing
of genes in the development of cancer. We compared the
frequency and extent of methylation of APC, CDKN2A,
ID4, MGMT, RBP1, RUNX3, SFRP1, TIMP3, and TMEFF2
in esophageal adenocarcinoma (EAC), high grade dys-
plastic Barrett's from patients with adenocarcinoma (D-
EAC), metaplastic Barrett's from patients without dyspla-
sia or adenocarcinoma (BE), and histologically normal
esophageal squamous epithelium. All nine genes showed
an increase in frequency of methylation in EAC compared
to squamous epithelium. We found that for seven of these
genes there was no difference in the frequency of methyl-
ation between the BE and EAC. For only CDKN2A and
RUNX3 was there a significant increase in frequency of
methylation in EAC compared to BE. The extent of meth-
ylation in EAC was significantly greater than in BE for six
of the nine genes (CDKN2A, ID4, RBP1, RUNX3, SFRP1
and TMEFF2) but was not different to D-EAC for any gene.
This suggests that methylation of these genes can occur
early in the development of Barrett's metaplasia, and for
only some of these genes does the extent of methylation
increases during the progression to cancer.
In the technique we used to analyse methylation, bisul-
phite modified DNA is amplified using primers and con-
ditions that do not discriminate between methylated and
unmethylated sequences. Amplification is therefore inde-
pendent of the presence or extent of methylation within
the region being assessed. Unlike two common methods
for measuring methylation, Methylation-Specific PCR [7]
or MethyLight [8], the method we used will detect small
amounts of methylation anywhere along the target
sequence. Thus the methylation frequency we measure
may differ from that reported by others. The methylation
extent reflects a combination of the percentage of the alle-
les that are methylated, and the density of methylation on
each allele. To determine if there was a relationship
between the methylation measured in our assays and tran-
scriptional silencing we measured gene expression in
esophageal cell lines treated with the demethylating drug
aza-dC. There was an increase in expression of ID4,
MGMT, RBP1, RUNX3, SFRP1 and TIMP3, suggesting an
association between methylation and silencing of expres-
sion for these genes. A relationship could not be deter-
mined for APC or CDKN2A, which were unmethylated, or
TMEFF2, for which we could not measure any transcript in
either cell line. For these three genes we have shown using
cell lines established from other cancers that methylation
of the regions we amplified are associated with gene
silencing (unpublished observations). In our EAC tissues
only methylation of MGMT was associated with a signifi-
cant reduction in mRNA expression. The lack of a signifi-
cant difference in gene expression for the other genes may
be due to methylation of only one allele, or the presence
of unmethylated cells in the tissue, such as clonal variants
of the tumor, or stromal or infiltrating cells. Methylation
in the cancer tissues was always greater than in the squa-
mous epithelium of patients without cancer, so even ifPage 5 of 12
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Number of methylated genes in esophageal tissuesFigur  3
Number of methylated genes in esophageal tissues. The number of methylated genes in specimens of squamous 
mucosa from patients without BE (S), squamous mucosa (S-BE) and columnar mucosa (BE) from patients with BE, and squa-
mous mucosa (S-EAC), high grade dysplastic Barrett's (D-EAC) and adenocarcinoma (EAC) from 38 patients with EAC.
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Expression and methylation in esophageal tissuesFigure 4
Expression and methylation in esophageal tissues. (a) Normalised mRNA expression of ID4, MGMT, RBP1, and SFRP1 
in squamous (S-EAC), high grade dysplastic Barrett's (D-EAC) or tumor (EAC) tissues from patients with EAC. (b) Normalised 
expression of ID4, MGMT, and RBP1 in tumors unmethylated or methylated for the gene. The horizontal bar represents the 
median expression.
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Molecular Cancer 2008, 7:75 http://www.molecular-cancer.com/content/7/1/75methylation did not result in gene silencing, it was still
associated with cancer.
The processes involved in the transition from squamous
epithelium to Barrett's metaplasia are unknown, although
chronic gastro-esophageal reflux is widely believed to be
the main trigger, with approximately 10% of gastro-
esophageal reflux patients having BE [9]. It is accepted
that BE is a pre-malignant condition, which over time, as
a result of the accumulation of multiple genetic and epi-
genetic modifications, can progress through dysplasia to
EAC in a percentage of patients. A large number of such
molecular changes have been reported in BE and EAC,
although the sequence of these changes appear not to be
as predictable as in some other cancers such as in the
colon [6].
It is not clear from the literature when aberrant DNA
methylation occurs during the progression to EAC. There
may be differences in molecular profile of BE tissue
obtained from cancer resection specimens, compared to
BE tissue obtained from patients with metaplasia only.
Our samples of BE were obtained from patients with no
detectable dysplasia or cancer, and were compared to can-
cer tissue from different patients. High levels of methyla-
tion in such BE specimens have been reported by others,
such as methylation of SFRP1 being as frequent in BE (81
– 100% of samples) as it is in EAC (93 – 100%) [10,11].
In several studies high levels of methylation have been
found in BE for many genes, but a few have reported low
methylation in BE and then high in EAC tissues. Eads et al
examined a single biopsy of metaplastic tissue from six
patients with BE without associated EAC and reported
methylation of APC, MGMT and TIMP3 in BE and also in
cancers from other patients, but they did not compare the
amounts of methylation in each [12]. They also reported
four genes, CDKN2A, ESR1 and MYOD1 and CALCA as
unmethylated in these BE patients, and methylated in the
cancers. Schulmann et al, using MethyLight, measured
methylation in 93 biopsies of BE from an undisclosed
number of patients [13]. Methylation was as frequent in
samples of EAC (n = 77) as in BE for APC, MGMT, RBP1
and TIMP3, but was significantly greater in EAC compared
to BE for CDKN2A, RUNX3 and TMEFF2. Furthermore,
the methylation level, their measure of the number of
extensively methylated or hypermethylated molecules in
the specimen, increased significantly from BE to dysplasia
for these three genes. Clement reported that APC, TIMP3
and TERT were significantly more methylated in BE of
patients who progressed to EAC compared to patients
with BE which had not progressed during a follow-up of
between four to ten years [10]. Of the nine genes which
we studied, only methylation of CDKN2A and RUNX3
appeared to increase in frequency in the progression from
BE to cancer, and only six of the nine genes increased in
the extent of methylation.
The underlying mechanisms that cause aberrant DNA
methylation in Barrett's metaplasia and cancer are
unknown. Our study confirms that aberrant methylation
of multiple genes is an early event, and mostly occurs
independently of dysplasia or EAC. Thus, we speculate
that methylation of some genes occurs at or shortly after
the transition from squamous to columnar metaplasia. To
date there are no longitudinal studies investigating meth-
ylation changes during metaplasia.
This is the first report of ID4 methylation in BE or EAC.
The other genes in this study have previously been
reported to be methylated in esophageal disease. ID4 is a
member of the inhibitor of DNA binding (ID) family of
proteins that inhibit the binding of basic helix-loop helix
transcription factors to DNA. It regulates the transcription
of genes important in development and differentiation,
and is a candidate tumor suppressor gene [14,15]. Meth-
ylation of ID4 has been reported in and associated with
the silencing of gene transcription and loss of protein
expression in lymphoma [16], and gastric [17], colorectal
[18] and breast carcinoma [19,20]. Methylation of ID4
correlated with increased risk of lymph node metastasis in
T1 stage breast cancer [20], and histopathological tumor
grade and poorer prognosis in colorectal carcinoma [18].
Our findings that ID4 is frequently methylated in BE and
EAC but not in the normal squamous mucosa and that
demethylation of cancer cell lines significantly increases
expression, suggests loss of ID4 expression is important in
the neoplastic progression of BE, supporting its role as a
tumor suppressor.
DNA methylation is not the only abnormality reported in
the genome of metaplastic Barrett's epithelium of patients
without dysplasia or EAC. Using gene expression microar-
rays, Wang et al reported that the gene expression profile
of BE more closely resembled EAC than esophageal squa-
mous epithelium. Rather than BE being a benign tissue,
they concluded that it was biologically closer to cancer
than to normal squamous epithelium [21]. Genomic loss,
chromosomal gains and amplifications, mutations, and
aneuploidy are observed in BE [22,23], and loss of heter-
ozygosity of CDKN2A is reported in 47 – 75% of patients
with BE, in the absence of dysplasia or EAC [24-26]. In
metaplastic epithelium from patients with dysplasia or
EAC, 5q (APC), 13q (RB1), 17p (TP53), and 18q (DCC)
are commonly lost, whilst 8q, 8p, and 6p are frequently
gained [27-29]. In contrast, mutations in BE are relatively
uncommon. Mutations in CDKN2A have been reported
in up to 7% of patients with metaplasia [24,30], but most
reports suggest that mutations are absent in BE from
patients without dysplasia or EAC [31].Page 8 of 12
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measured little methylation in any esophageal squamous
epithelium, but in BE tissues there was significant methyl-
ation which for all but two of the nine genes examined did
not increase in frequency in the progression from BE to
EAC. We have also reported methylation of ID4 for the
first time in BE or EAC. Together these findings confirm
that BE is a precancerous tissue, and that aberrant pro-
moter methylation occurs early in metaplasia before his-
tological evidence of progression towards cancer, and that
metaplastic BE is nearly as abnormal epigenetically as
EAC.
Methods
Patient samples
Single samples of primary esophageal adenocarcinoma
(EAC, n = 37), dysplastic Barrett's (D-EAC, n = 7) and his-
tologically normal squamous mucosa from the proximal
resection margin (S-EAC, n = 21) from 38 patients with
EAC were collected into liquid nitrogen or into RNAlater
(Ambion, Austin, TX, USA). Multiple biopsies every 2 cm
from within circumferential columnar lined esophagus
(BE, n = 40) and a single biopsy of squamous mucosa
proximal to the squamo-columnar junction (S-BE, n = 16)
from 18 patients with BE were collected into RNAlater.
The presence of goblet cells in at least one biopsy from the
columnar lined esophagus was confirmed in all patients
with BE. Up to three biopsies of squamous mucosa (S, n =
19) from each of seven patients without a known history
of BE, but who had undergone a fundoplication for gas-
tro-esophageal reflux disease more than five years earlier,
were collected into RNAlater. Clinicopathological details
of all patients are summarised in Table 2, and details of
each patient are described in Additional Files Tables S1 –
S3. The study complied with the appropriate institutional
guidelines.
Demethylation of cell lines with 5-aza-2'-deoxycytidine
To study the effects of demethylation, triplicate cultures of
the esophageal cancer cell lines OE33 and TE7 [32] were
grown in RPMI 1640 supplemented with 10% foetal
bovine serum at 37°C in 5% CO2. The OE33 cell line was
established from a Barrett's associated adenocarcinoma of
the lower esophagus, and the TE7 is thought to be derived
from a squamous cell carcinoma of the esophagus [33].
Cells were seeded into flasks and cultured for 24 hours
before they were treated with either 1 μmol/L 5-aza-2'-
deoxycytidine (aza-dC, Sigma-Aldrich, Saint Louis, MO)
or vehicle (0.0027% v/v final concentration acetic acid).
Following a further 72 hours incubation, time for the cells
to undergo at least two cycles of division [34], the
medium was replaced with fresh medium not containing
either aza-dC or vehicle, and the cells incubated for a fur-
ther 24 hours before harvesting.
Isolation of RNA and DNA from cell lines and patient 
samples
Tissues were disrupted using either disposable pestles
(Edwards Instruments, Narellan, NSW, Australia) or Tis-
sueLyser with 5 mm Stainless Steel Beads (Qiagen,
Hilden, Germany). RNA and DNA were isolated from cell
lines and tissues from patients with EAC using Trizol (Inv-
itrogen, Carlsbad, CA). RNA and DNA were isolated from
all other biopsies using either the RNA/DNA Kit or the All-
Prep DNA/RNA Mini Kit (Qiagen).
Methylation analysis
Bisulphite modified DNA was prepared as described pre-
viously [34,35], and amplified using primer sets which
did not discriminate between methylated and unmethyl-
ated sequences. The PCR primers (GeneWorks, Thebar-
ton, SA, Australia) and conditions were specific for
bisulphite modified DNA, and did not amplify unmodi-
fied DNA. All methylation analysis PCRs were performed
using the QuantiTect SYBR Green PCR Kit (Qiagen) in a
final volume of 15 μL, containing 1 μL of bisulphite mod-
ified DNA and a final concentration of 0.5 μmol/L of each
forward and reverse primer. Bisulphite modified lym-
phocyte DNA, CpG methyltransferase (M.SssI) (New Eng-
land Biolabs Inc., Ipswich, MA) treated lymphocyte DNA
and unmodified DNA were included in each PCR run and
served as unmethylated, methylated and negative controls
respectively. Reactions were incubated in a Rotor-Gene
3000 (RG-3000) (Corbett Life Science, Sydney, NSW, Aus-
tralia) at 95°C for 15 minutes, then 45 cycles of 95°C for
30 seconds and 60 seconds at the annealing temperature
specified in Table 2, followed by a final extension of 72°C
for 4 minutes. At the end of the amplification cycle the
PCR products were melted by increasing the temperature
from 60 to 95°C, rising 0.5 or 1°C at each step, waiting 30
seconds on the first step then 5 seconds for each step
thereafter. Data was collected and analysed using the Melt
Curve Analysis function of the RG-3000 Application Soft-
ware v6 (Corbett Life Science) which converts the raw flu-
Table 2: Demographic characteristics of patients
EAC BE Without BE or EAC
Number of patients 38 18 7
M:F 34:4 18:4 2:7
Median age, yr (range) 64 (51 – 78) 56 (38 – 71) 60 (37 – 76)Page 9 of 12
(page number not for citation purposes)
Molecular Cancer 2008, 7:75 http://www.molecular-cancer.com/content/7/1/75
Page 10 of 12
(page number not for citation purposes)
Table 3: The primer sequences and annealing temperatures for qRT-PCR
Gene Forward primer Reverse primer Annealing temperature (°C)
APC TGGAGAACTCAAATCTTCGACA CAATCTGTCCAGAAGAAGCCATA 62
CDKN2A GAGGCCGATCCAGGTCAT CCAGCGTGTCCAGGAAG 62
HMBS ACATGCCCTGGAGAAGAATG TTGGGTGAAAGACAACAGCA 57
ID4 CCGAGCCAGGAGCACTAGAG CTTGGAATGACGAATGAAAACG 60
MGMT TGGAGCTGTCTGGTTGTGAG GCTGGTGGAAATAGGCATTC 60
RBP1 AGGCATAGATGACCGCAAG CTCATCACCCTCGATCCAC 62
RUNX3 GCAGGCAATGACGAGAACTA CAGTGATGGTCAGGGTGAAA 57
SFRP1 TTGAGGAGAGCACCCTAGGC TGTGTATCTGCTGGCAACAGG 60
TIMP3 CCAGGACGCCTTCTGCAAC CCTCCTTTACCAGCTTCTTCCC 60
TMEFF2 CAATGGGGAGAGCTACCAGA TGGACTCCATCTCCAGATCC 62
Table 4: Table S1 – Demographic details of patients with EAC.
Patient Gender Age(yr) Differentiationa S-EACb D-EACb EACb
0226 M 53 P + - +
0227 M 58 M + + -
0230 M 77 M-P + + +
0235 M 61 M + - +
0246 F 62 W + + +
0250 M 68 M-P + + +
0253 M 77 M-P + - +
0292 M 55 M + - +
0306 M 68 P + - +
0307 M 58 M + - +
0316 M 69 P + + +
0329 M 67 P - - +
0339 F 63 P + - +
0343 F 62 P - - +
0347 M 56 P + - +
0355 F 62 P + - +
0369 M 75 M + - +
0374 M 65 M + - +
0375 M 72 M + - +
0380 M 57 M + - +
0385 M 70 M + - +
0406 F 53 M + - +
0410 M 62 M + - +
0415 M 56 P - + +
0417 M 73 P - + +
40320 M 61 M - - +
40323 M 60 P - - +
40325 M 61 M-P - - +
40328 M 65 M - - +
40331 M 64 P - - +
40337 M 70 P - - +
40338 M 71 W - - +
40341 M 78 P - - +
40345 M 60 M - - +
40355 M 65 M-P - - +
40357 M 65 M-P - - +
53145 M 51 M - - +
54017 M 76 P - - +
aW, well; M, moderate; P, poor
b+ tissue available; – no tissue available
Molecular Cancer 2008, 7:75 http://www.molecular-cancer.com/content/7/1/75orescence data to melt curves by plotting the negative first
derivative of the fluorescence with respect to temperature
(-dF/dT), against temperature. The melt curve of the sam-
ple was compared to those of the unmethylated and
methylated controls. A sample was considered methylated
when there was a visible shift to the right of the unmeth-
ylated melt curve. The methylation extent, a function of
both the number of alleles which are methylated and the
density of methylation in each allele, was graded as 0
(unmethylated), 1 (low), 2 (moderate), or 3 (high meth-
ylation) according to the degree of the shift [35]. Briefly, a
curve which was almost identical to the methylated con-
trol was scored as 3, a curve whose melting temperature
was closer to methylated control than the unmethylated
control was scored as 2, a curve which was almost identi-
cal to unmethylated control was scored 0 and the rest were
scored as 1. All assessment was undertaken independently
by two investigators (E.S. and P.A.D.), and if their opin-
ions differed, consensus was reached by discussion.
Measurement of gene expression by quantitative real-time 
reverse-transcription PCR
To measure gene expression, cDNA was synthesised using
SuperScript II (Invitrogen) from 2 μg of RNA which had
been treated with the TURBO DNA-free Kit (Ambion).
Quantitative real-time reverse-transcription PCR (qRT-
PCR) was performed using the QuantiTect SYBR Green
PCR Kit in a final volume of 10 μL, containing 1 μL of 1/
5 diluted cDNA and a final concentration of 0.5 μmol/L
of each forward and reverse primer. Triplicate reactions
were incubated in an RG-3000 at 95°C for 15 minutes,
then 45 cycles of 95°C for 15 seconds and 45 seconds at
the annealing temperature specified in Table 3, followed
by a final extension of 72°C for 4 minutes. Data was col-
lected and analysed using the RG-3000 Application Soft-
ware. Threshold cycle Ct values were determined on auto-
threshold settings with reference to a standard dilution
curve. All mRNA quantitation data was normalised to
hydroxymethylbilane synthase (HMBS) [34]. Following
the PCR, the products were melted to confirm specificity,
and electrophoresed on 1.5% (w/v) agarose gels stained
with ethidium bromide to confirm expected product size.
Statistical analyses
Statistics were performed using GraphPad InStat version
3.0a or Prism version 5.0a for Macintosh (GraphPad Soft-
ware, San Diego California USA, http://www.graph
pad.com). Gene expression in cell lines treated with either
aza-dC or vehicle was compared using Student's t-test.
Methylation frequency in tissues was compared using
Fisher's exact test. The number of methylated genes in a
specimen and gene expression was compared using
Kruskal-Wallis with Dunn's post-test. Methylation extent
and gene expression in unmethylated and methylated tis-
sues was compared using the Mann-Whitney test. All sta-
tistics were considered significant when the two tailed P ≤
0.05.
Conclusion
We have measured methylation of genes in BE and EAC
and found significant methylation in metaplastic BE,
which for seven of the nine genes studied did not differ in
frequency from that found in EAC. This study provides
important confirmatory evidence to support the concept
that BE is a highly abnormal tissue, more similar to cancer
tissue than to normal squamous epithelium.
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